Congestive heart failure is associated with extracellular matrix (ECM) remodeling resulting from an imbalance in the synthesis and degradation of ECM collagen.
Congestive heart failure is associated with extracellular matrix (ECM) remodeling resulting from an imbalance in the synthesis and degradation of ECM collagen. 1, 2) Severe degrees of cardiac remodeling are associated with an increased risk of heart failure, morbidity, and mortality in patients with heart failure. 3, 4) Neurohumoral activation plays a key role in compensatory mechanisms and myocardial remodeling in patients with heart disease, and is accompanied by the expression of matrix metalloproteinases (MMPs). 2, 3, 5, 6) The MMPs compose a family of enzymes that contribute to ECM remodeling in several disease states, by promoting ECM degradation. Interestingly, several studies have shown that increased MMP expression and activation are involved in myocardial remodeling processes associated with several heart diseases. 4, [7] [8] [9] In addition, animal models of heart disease showed increases in MMP activity and left ventricular (LV) remodeling. [10] [11] [12] Likewise, MMP inhibition and deletion are reported to prevent LV remodeling and dysfunction, suggesting the potential usefulness of MMP inhibitors (MMPi) in patients with heart failure. Spontaneously hypertensive rats showed increased collagen accumulation and MMP activation, which were reversed after treatment with an MMPi. 6) MMP knockout mice showed preserved cardiac function and decreased myocardial fibrosis in myocardial infarction. 13, 14) Furthermore, the MMPi doxycycline was reported to prevent cardiac hypertrophy, MMP activity, and myocardial fibrosis in rats with myocardial ischemia. 15) However, few studies have examined the effects of doxycycline on b-agonist-induced myocardial fibrosis. Therefore, we investigated the effects of doxycycline on isoproterenol-induced myocardial fibrosis and MMP expression.
MATERIALS AND METHODS
Four-week-old Wistar-Kyoto rats (nϭ42) were obtained from a commercial laboratory (Charles River, Yokohama, Japan). The rats were housed individually in an air-conditioned room with a 12-h dark-light cycle and were given a standard diet with ad libitum access to tap water. The rats were divided into 3 groups: control (CTL), isoproterenol (ISO), and isoproterenol with doxycycline (ISOϩDOX). This study was approved by the Institutional Laboratory Animal Care and Use Committee of the School of Veterinary Medicine of Kitasato University, Japan.
Study 1 Four-week-old rats (nϭ18; body weight, 90-110 g) were divided into 3 groups: control (nϭ6), ISO (nϭ 6), and ISOϩDOX (nϭ6). Animals were anesthetized with an intraperitoneal injection of pentobarbital (50 mg/kg). A 3Fr catheter was implanted into the jugular vein and the drug was administered with an infusion pump (Nihon Kohden, Tokyo, Japan). The rats were stabilized for 15 min and placed in the prone position above an ultrasound standoff pad (3M Health Care Ltd., Tokyo). Control rats were infused 0.9% saline alone. L-Isoproterenol (Sigma-Aldrich Co., St. Louis, MO, U.S.A.) was infused at 0.5 and 1.0 mg/kg/min for 5 min. In ISOϩDOX rats, doxycycline hydrochloride was infused at 17-18 mg/kg/min (25 mg/kg/d; Sigma-Aldrich Co.) concomitant with L-isoproterenol.
Echocardiographic Measurements The heart rate was monitored using an echocardiographic system. As an index of left ventricular contractility, fractional shortening (FS) was measured by echocardiography using a 12-MHz probe (Philips Electronics Japan, Tokyo, Japan 
The average of three cardiac cycles was calculated. Data were stored digitally and analyzed off-line by a single observer. All measurements were performed before and after administering the isoproterenol.
Study 2 Seven-week-old rats (nϭ24; body weight, 200-280 g) were divided into 3 groups: CTL (nϭ8), ISO (nϭ8), ISOϩDOX (nϭ8). After being anesthetized, rats were aseptically implanted with a subcutaneous osmotic minipump (model 2002, Alzet, Durect Co., U.S.A.) through a small interscapular incision. These minipumps were used to deliver 2.0 mg/kg/d of L-isoproterenol dissolved in a 0.9% saline for 14 d. Control rats were implanted with minipumps containing vehicle (0.9% saline) alone. During the treatment period, rats were also given a subcutaneous injection of doxycycline hydrochloride (ISOϩDOX rats; 25 mg/kg/d, 0.5 ml bis in die (BID)) or saline (CTL and ISO rats; 0.5 ml, BID).
Tissue Sampling After 14 d of treatment, the hearts were excised with the use of sodium pentobarbital (50 mg/kg, intraperitoneally (i.p.)) anesthesia. The heart was divided into the right ventricle (RV) and LV, including the septum, in ice-cold saline. The whole heart weight (HW) and the LV weight (LVW) were measured, corrected for body weight, and used to determine the HW/BW and LVW/BW ratios. The hearts were cut into coronal sections at the level of the papillary muscles; the basal part of the heart was fixed in 10% formalin, and the apex of the heart was snap-frozen in liquid nitrogen.
Histopathological Analysis Fixed hearts were embedded in paraffin and transverse sections (4 mm) were cut and stained by routine methods. Azan stain was used to detect collagen. To determine the degree of cardiac fibrosis, images of Azan-stained samples were transferred into a computer using a microscope. A minimum of 10 fields from each LV section were scored at 100ϫ magnification. The degree of cardiac fibrosis was determined based on the area of fibrosis divided by the total area (%cardiac fibrosis). A minimum of 100 cells from each LV section at 400ϫ magnification were stored. The myocyte cross-sectional area (MCSA) of each cell was measured by computer-based planimetry. The images were imported into the NIH Image Program (National Institutes of Health), which was used for quantitative analysis of the Azan-stained fibrotic region.
Western Blotting Western blotting analyses for MMP-2 or -9 were performed according to a modification of a method described previously. 16, 17) Frozen tissue was homogenized in lysis buffer [50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 1 mM EDTA2Na, 0.5% Triton X-100], centrifuged at 12000ϫ g for 15 min, and the resultant supernatant was used for analysis. Protein content was determined using the Bradford technique. Tissue lysates were diluted in sample buffer [125 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 0.04% bromophenol blue, 10% b-mercaptoethanol], boiled for 5 min, and aliquots of 15 mg were separated by electrophoresis on 10% polyacrylamide gels. The separated proteins were transferred onto polyvinylidene fluoride (PVDF) membranes (Immobilon RP, Millipore, U.S.A.) and stained with amide black to visualize proteins. Nonspecific binding sites were blocked with 0.5-1% fat-free milk containing Tris-buffered saline with 0.05% Tween 20 (TBST) at room temperature for 30 min. After washing with 0.05% TBST, membranes were incubated overnight at 4°C with monoclonal antibodies specific for MMP-2 (dilution, 1 : 1000; Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) and MMP-9 (dilution, 1 : 2000; Chemicon International, Temecula, CA, U.S.A.). Membranes were subsequently washed with TBST and the immobilized primary antibody conjugated with a horseradish peroxidaselabeled secondary antibody (Santa Cruz Biotechnology) diluted 1 : 20000 in TBST for 3 h at room temperature. After a thorough washing with TBST, proteins were visualized with peracid and luminol (ECL Western blotting detection reagents, Amersham Life Science, U.K.). Quantification of protein expression was performed using the commercial analysis software package supplied with the system (Alpha Ease FC, Alpha Innothech Co., CA, U.S.A.).
MMP Zymography Protein was extracted from the frozen ventricle by homogenization. 16, 17) Briefly, homogenates were re-suspended in lysis buffer, centrifuged at 12000ϫg, and protein concentration was determined using the Bradford technique. Samples were diluted in sample buffer [125 mM Tris-HCl (pH 6.8), 20% glycerol, 4% SDS, 0.04% bromphenol blue] and aliquots with a final protein content of 5 mg were separated by 10% SDS-polyacrylamide electrophoresis (SDS-PAGE) on gels containing 0.6% gelatin. After SDS-PAGE, the gels were washed twice in extraction buffer [20 mM Tris-HCl (pH 7.5), 2 mM CaCl 2 , 1 mM ZnCl 2 , 0.02% NaN 3 , 2.5% Triton X-100] for 30-min each time and rinsed in water. Gels were incubated at 37°C overnight in incubation buffer [20 mM Tris-HCl (pH 7.5), 2 mM CaCl 2 , 1 mM ZnCl 2 ], stained with Coomassie staining solution (0.5% Coomassie R250, 30% methanol, 10% acetic acid) for 2 h, and then de-stained in distilled deionized H 2 O. The MMP marker was used as a control (Gelatin Zymo MMP Marker, Life Laboratory Co., Yamagata, Japan). Gelatinolytic bands were quantified as described above.
Statistical Analysis All numerical data are expressed as meanϮS.D. Changes in echocardiographic measurements, heart rate and FS were compared to baseline using a one-factor repeated measures analysis of variance (ANOVA). These measurements from baseline were compared to the control group using two-way ANOVA. Histopathological analysis, Western blotting, and MMP zymography were compared using one-way ANOVA. The significances of differences between the mean values at baseline and under each condition were tested using Tukey's multiple comparison test. The differences were considered significant at a p-value of Ͻ0.05.
RESULTS

Study 1
Isoproterenol administration significantly increased the heart rate from baseline in ISO and ISOϩDOX groups (pϽ0.05 for both; Fig. 1A) . Similarly, isoproterenol administration significantly increased the FS from baseline in ISO (pϽ0.01 and pϽ0.001, respectively) and ISOϩDOX groups (pϽ0.05 and pϽ0.01, respectively; Fig. 1B ). These responses were insignificant between ISO and ISOϩDOX groups, but were significantly elevated compared to those in the CTL group (HR; pϽ0.05 for both, FS; pϽ0.001 for both).
Study 2 The HW/BW and LVW/BW ratios increased significantly in the ISO and ISOϩDOX groups compared to the control (Table 1) , but did not differ between the ISO and ISOϩDOX groups. Compared with the controls, the MCSA were significantly increased by ISO treatment. Compared to ISO treatment, ISOϩDOX treatment significantly decreased the MCSA. Pathological findings for each group are shown in Fig. 2 . The percent fibrotic area increased significantly in the ISO and ISOϩDOX groups compared to the control (pϽ 0.001 for both), but decreased significantly in the ISOϩDOX group compared to the ISO group (pϽ0.05).
ProMMP-2 activity increased significantly in the ISO group compared to the control (pϽ0.001), but decreased significantly in the ISOϩDOX group compared to the ISO group (pϽ0.01, Fig. 3 ). ProMMP-2 activity did not differ between the ISOϩDOX and CTL groups. No MMP-9 activity was detected in heart tissue via zymography. Immunoblotting revealed significant increases in MMP-2 and -9 protein expression in the ISO group compared to the control (pϽ0.01 for both), but significant decreases were observed in the ISOϩDOX group compared to the ISO group (pϽ0.01 and pϽ0.05, respectively; Figs. 4 and 5). MMP-2 and -9 levels did not differ significantly between the ISOϩDOX and CTL groups.
DISCUSSION
Isoproterenol is a well-known b-adrenoceptor agonist that produces inotropic and chronotropic effects in a dose-dependent manner. [18] [19] [20] Our findings were consistent with previous studies, which have shown that isoproterenol induces an increase in heart rate and FS. In animals, isoproterenol has been shown to enhance LV cardiac systolic and diastolic function and heart rate. [19] [20] [21] Therefore, the cardiac responses to isoproterenol observed in the present study represented typical reactions. Although doxycycline is a broad spectrum antibiotic with MMP inhibition, it is not clear yet whether or not it directly inhibits b-adrenoceptor. In the present study, doxycycline did not affect the cardiac responses to b-adrenoceptor stimulation (data shown in Fig. 1 ). These results indicated that doxycycline did not directly inhibit badrenoceptor stimulation; however, it may affect the badrenoceptor signaling pathway. Removal of doxycycline for 10 d was associated with significant increase in cardiac adenylycyclase type VI compared to receiving doxycycline continuously, which is consistent with the cAMP production increase in response to isoproterenol and the systolic function increase in response to dobutamine. 22) In isolated rat mesenteric arteries, selective stimulation of a 1 -adrenoceptors with phenylephrine induced MMP transactivation of the epidermal growth factor receptor, mitochondrial reactive oxygen species (ROS) production and vasoconstriction. Adrenoceptor-induced ROS production and vasoconstriction were prevented by MMP inhibitor, but not high K ϩ -preconstricted arteries. 23) Further studies are required to investigate the relationship between MMPi and b-adrenoceptor signaling pathway.
Neurohormonal activation of systems such as the sympathetic nervous system or the renin-angiotensin-aldosterone system is the predominant cause of myocardial fibrosis in patients with heart disease. 2, 17, 24) In addition, collagen accumulation impairs cardiac function, which is associated with the development of heart failure. 3, 25) Recent clinical studies have reported increased MMP expression and activation in myocardial fibrosis associated with several heart diseases, including aortic stenosis, hypertrophic cardiomyopathy, and dilated cardiomyopathy. 4, [7] [8] [9] Patients with hypertrophic cardiomyopathy had higher levels of procollagen type III aminoterminal propeptide and collagen I carboxy-terminal telopeptide than normal subjects, concomitant with MMP-2 and -9 expression. 4) In patients with aortic stenosis, the expression/ activation of MMPs and collagen accumulation increased in proportion to disease severity. 8) Similarly, myocardial fibrosis was aggravated in animal models of heart disease, in association with the expression and activation of MMPs. 16, 17) Transgenic mice over-expressing MMP-1 showed marked deterioration of cardiac function. 26) In addition, previous studies showed that isoproterenol causes myocardial hypertrophy and apoptosis through the augmentation of mitogen-activated protein kinase (MAPK) expression, which related to the expression/activation of MMPs. [27] [28] [29] [30] In the present study, 2-week administration of isoproterenol induced cardiac hypertrophy and myocardial fibrosis and increased MMP-2 and -9 protein expression. Our results are consistent with those of previous reports indicating that b-agonists augment myocardial apoptosis, hypertrophy, and MMP activation in rats. 2, 30, 31) These observations suggest that MMP synthesis/activation is enhanced by the isoproterenol administration and is associated with myocardial fibrosis.
MMPs are known to play a significant role in collagen turnover in pathophysiological processes. 10, 13) Selective MMPi treatment inhibited MMP activity and subsequently preserved cardiac function and attenuated LV enlargement in a porcine heart disease model. 32) In other studies, a selective MMPi prevented collagen accumulation and MMP activation and preserved cardiac function in animal models of chronic heart failure. 6, 33) In addition, MMP-9 knockout mice and rats receiving tissue inhibitor of metalloproteinase (TIMP)-1 gene transfer showed significantly preserved cardiac function and attenuated LV enlargement and collagen accumulation. 13, 34) Furthermore, the survival rate was significantly higher in MMP-2 knockout mice with myocardial infarction than in control mice. 14) Doxycycline is a common tetracycline antibiotic, and is a broad-spectrum inhibitor of MMP expression and activity. 35) Previous studies showed that pre-treatment with doxycycline reduced infarct size in rats, 36) and that early short-term treatment with doxycycline after myocardial infarction preserved left ventricular structure (i.e., heart weight, myocyte size, and internal LV diameter). 37) Similarly, Errami et al. reported that although isoproterenol causes cardiac hypertrophy and MMPs expression/activation through the augmentation of MAPK expression in mice, doxycycline attenuated these effects. 30) In vitro, doxycycline prevented myocardial apoptosis, as evidenced by the frequency of TUNEL-positive cells, and decreased MMP-2 and caspase-3 activity in myocytes treated with tumor necrosis factor (TNF)-a. 38) In the present study, doxycycline treatment attenuated MMP expression/activity, resulting in decreased fibrosis in the rat myocardium during chronic isoproterenol administration. Although doxycycline significantly decreased MCSA, it slightly, but not significantly decreased cardiac hypertrophy. Regarding the inconsistency in cardiac hypertrophy with a previous report, this may be explained by methodological differences, i.e. different doses and durations of isoproterenol or different species: Errami et al. administered isoproterenol (40 mg/kg/d) and doxycycline (6 mg/kg/d) for 7 d in mice, but we administered the same drugs for 14 d in rat at, respectively, 2 mg/kg/d and 25 mg/kg/d. These results indicate that the broad-spectrum MMPi, doxycycline, prevents isoproterenol-induced myocardial fibrosis and MMP expression/activity.
Limitation We examined the relationship between myocardial fibrosis and MMP expression/activity. Because doxycycline is not a selective inhibitor and can also inhibit other proteases, further studies are required to clarify the mechanisms by which MMPi attenuates myocardial fibrosis. However, the optimal therapeutic dose of doxycycline is yet to be determined and it is possible that treatment with it at different doses and durations may have different results. 5, 27) Other properties of doxycycline, such as the inhibition of protein and collagen synthesis, may have adverse effects on LV remodeling. 12, 13, 39) Finally, doxycycline is the only MMPi currently approved for clinical use, but its application is limited to the treatment of periodontal disease.
CONCLUSION
In the present study, chronic administration of the b-agonist isoproterenol induced myocardial fibrosis and was associated with increased MMP expression and activity. Furthermore, doxycycline prevented MMP expression/activity and myocardial fibrosis. These results suggest that enhanced MMP expression plays a prominent role in b-agonist-related myocardial fibrosis, and that MMP-inhibiting compounds may attenuate this condition.
